 REDWOOD CITY, Calif., May 12, 2021 GLOBE NEWSWIRE -- Adverum Biotechnologies, Inc. Nasdaq: ADVM, a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that, based on a preliminary vote count provided by its proxy solicitors following its 2021 Annual Meeting of Stockholders, stockholders have voted to re-elect all three of Adverums highly qualified director nominees Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. to the Adverum Board of Directors, ratified the selection of Ernst Young LLP as independent auditors and approved, on an advisory basis, the compensation of Adverums named executive officers. 